IDEAYA Biosciences

91 articles with IDEAYA Biosciences

• IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma

  11/29/2021

  IDEAYA Biosciences, Inc. announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma .

• IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/15/2021

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2021.

• IDEAYA Biosciences to Participate in Investor Conferences in November 2021

  11/1/2021

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2021.

• IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer

  10/18/2021

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Michael White, Ph.D., will join the company as its Chief Scientific Officer, effective November 1, 2021.

• IDEAYA Biosciences to Participate in Investor Conferences in September 2021

  8/30/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in September 2021.

• IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/10/2021

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2021.

• IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021

  8/2/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in a panel discussion at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021.

• IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  7/12/2021

   IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions, including the exercise in full by the underwriters of their option to purchase up to an additional 695,652 shares of common stock in the offering

• IDEAYA Announces Pricing of Public Offering of Common Stock - July 08, 2021

  7/8/2021

  IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions.

• IDEAYA Announces Proposed Public Offering of Common Stock - July 06, 2021

  7/6/2021

  IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $80 million of shares of its common stock in an underwritten public offering.

• IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination

  6/28/2021

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updates for its Phase 1 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion and Phase 1/2 clinical trial evaluating darovasertib combination therapies in metastatic uveal melanoma.

• IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

  5/24/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 2021 Jefferies Virtual Healthcare Conference.

• IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Strong balance sheet of ~$325 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2024

• IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

  5/10/2021

  Initiated darovasertib plus crizotinib combination Phase 1/2 dose expansion based on early clinical activity observed in first cohort; additional dose exploration ongoing

• IDEAYA to Participate in Upcoming May 2021 Investor Relations Event

  5/6/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations event.

• IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

  4/19/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.

• IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

  4/16/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 1/2 trial evaluating darovasertib monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma and Skin Melanoma.

• IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors

  4/15/2021

  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 clinical trial evaluating IDE397 (ClinicalTrials.gov Identifier: NCT04794699)

• IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

  4/15/2021

  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the company plans to issue a pre-market press release and conduct a webcast on Friday, April 16, 2021, to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib

• IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

  3/23/2021

  Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion